Skip to main content
SpringerLink
Log in

Antibiotics—an investment worth making?

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Antibiotics markets are huge and the need for new classes of antibiotics is great, but the risks give investors pause.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The antibiotics market is over $25 billion in size, although much of it comprises generic sales.

References

  1. Anonymous. Nat. Rev. Drug Discovery 5, 446–447 (2006).

Download references

Author information

Authors and Affiliations

  1. General Partner at Morgenthaler Ventures, 4430 Arapahoe Avenue, Suite 220, Boulder, 80303, Colorado, USA

    Ralph E Christoffersen

  2. Morgenthaler is an investor in Replidyne, Inc., and Christoffersen is a member of the Board of Directors of Replidyne,

    Ralph E Christoffersen

Authors
  1. Ralph E Christoffersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christoffersen, R. Antibiotics—an investment worth making?. Nat Biotechnol 24, 1512–1514 (2006). https://doi.org/10.1038/nbt1206-1512

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1512

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation